Home - Metacrine

There are more than 3 million people in the United States with IBD.

We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with GI and liver diseases.

Our most advanced program targets the farnesoid X receptor (FXR) which is central to modulating GI and liver diseases.